What is the Daehwa Pharm Co. Ltd. stock price forecast?

Daehwa Pharm Co. Ltd. is currently trading at ₩11,080. View real-time AI analysis on Alpha Lenz.

What is Daehwa Pharm Co. Ltd. insider trading activity?

View the latest insider trading data for Daehwa Pharm Co. Ltd. on Alpha Lenz.

What is Daehwa Pharm Co. Ltd.'s P/E ratio?

Daehwa Pharm Co. Ltd.'s P/E ratio is 124.7.

Daehwa Pharm Co. Ltd.

KRX · 067080

₩11,080+630(+6.03%)Market closed

Ask about Daehwa Pharm Co. Ltd.'s future dividend policy...

Alpha Chat Insight

“Daehwa Pharm Co. Ltd. trades at a P/E of 124.7 (premium valuation) with modest ROE of 2.3%.”

Ask for details →

Company Overview

Daehwa Pharm Co. Ltd. is a South Korean pharmaceutical company known for its development and manufacturing of innovative healthcare solutions. The company's primary function is to research, develop, and market pharmaceutical products, focusing on patient care and enhancing health outcomes. Daehwa Pharm specializes in a wide range of therapeutic areas, including oncology, cardiovascular diseases, and metabolic disorders. It plays a pivotal role in the healthcare industry by introducing advanced drug formulations and treatment methodologies that cater to the growing global demand for better health management. With a commitment to rigorous scientific research and a robust portfolio of patents, Daehwa Pharm Co. Ltd. contributes significantly to the pharmaceutical sector through collaborative partnerships with research institutions and healthcare providers, thus sustaining its role as a vital player in the global market.

CEO김은석(단독대표)

Websitehttps://www.dhpharm.co.kr

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Company Statistics

FY 2025

Profile

₩206,272,482,000Market Cap

₩143,060,002,180Revenue

18.62MShares Out

0Employees

Margins

33.43%Gross

7.81%EBITDA

2.21%Operating

3.34%Pre-Tax

1.63%Net

Valuation

124.75P/E

2.78P/B

1.44EV/Sales

27.45EV/EBITDA

294.70P/FCF

Growth (CAGR)

2.74%Rev 3Yr

5.52%Rev 5Yr

-18.52%Op Inc 3Yr

-4.31%Op Inc 5Yr

24.03%Net Inc 3Yr

N/ANet Inc 5Yr

Returns

1.12%ROA

2.26%ROE

4.59%ROIC

Financial Health

₩1,356,705,500Cash & Cash Equivalents

₩130,364,848,680Net Debt

166.44%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Daehwa Pharm Co. Ltd. trades at a P/E of 124.7 (premium valuation) with modest ROE of 2.3%.”

Ask for details →

Frequently Asked Questions

Daehwa Pharm Co. Ltd. (ticker: 067080) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $206.3B.

The current price is ₩11,080 with a P/E ratio of 124.75x and P/B of 2.78x.

ROE is 2.26% and operating margin is 2.21%. Annual revenue is $143.1B.